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In a recent issue of Science, Olive and colleagues document that inhibition of Hedgehog (Hh) signaling in
a genetically engineered mouse model of pancreatic cancer can enhance the intratumor concentration of
certain anticancer drugs. Could this finding provide us with a new method to attack pancreatic cancer?Pancreatic cancer remains a major chal-
lenge for all of us. It is the fourth leading
cause of death from cancer in the US,
with an estimated 37,680 people diag-
nosed with the disease and 34,280 people
dying from the disease each year (Jemal
et al., 2008). Worldwide, more than
213,000 are diagnosed with pancreatic
cancer each year (Koorstra et al., 2008).
It has the worst 1 and 5 year survival of
any cancer. In addition to a poor survival
rate, patients with pancreatic cancer
have a great deal of suffering, with a parti-
cularly high incidence of pain—mostly
caused by a predilection for the tumor to
invade the perineural space of nerves in
the celiac plexus (Zhu et al., 1999). In addi-
tion, substantial weight loss and multiple
gastrointestinal symptoms sap the energy
of patients with the disease. If the above
description of the disease is not bad
enough, there has recently been worse
news (Jones et al., 2008). In a comprehen-
sive genetic analysis of 24 patients’
pancreatic cancers, the authors noted an
average of 63 genetic alterations in each
tumor, the majority of which were point
mutations. However, these alterations
did define a set of 12 recurrent pathways
as possible ways to attack the disease;
the findings remind us just how chal-
lenging pancreatic cancer is to treat.It is a mystery as to why so many
currently available anticancer agents
with demonstrated antitumor activity in
in vitro and in vivo tumor models do not
work in patients with pancreatic cancer.
Is it just because of the inherent resistance
or heterogeneity of pancreatic cancer?
Other tumors, such as colon and lung,
have inherent resistance and heteroge-
neity, yet anticancer agents frequently
cause tumor shrinkage and improve
survival for patients with those diseases.
Why is this?
It has been recognized for some period
of time that pancreatic cancers often
demonstrate hypoperfusion (Park et al.,
2009) (Figure 1). Microscopically, almost
a sine qua non of pancreatic cancer
is the dense fibroinflammatory reaction
that invariably accompanies the disease
(Mahadevan and Von Hoff, 2007). This
appearance is also noted with other types
of cancer, such as breast cancer. Could it
be so simple that hypoperfusion explains
why any therapeutic agent simply cannot
get to the tumor cells because the circula-
tion to pancreatic cancer is so poor?
Pancreatic cancer is one of the tumor
types to be consistently hypoxic, possibly
because of hypoperfusion, and it is notori-
ously resistant to antiangiogenic agents
(Van Cutsem et al., 2009). If hypoperfusionCanceis the reason (or at least one of the
reasons) for the resistance of pancreatic
cancers to our therapies, Olive and col-
leagues (2009) have now given us a new
window on how the stroma (the fibroin-
flammatory component of the tumor) may
be altered, possibly improving our ability
todeliveranticancer therapies to the tumor
cells.
Ina seriesof well-strategized and careful
pieces of work, Tuveson and colleagues
have generated genetically engineered
mouse models that closely mimic the
human disease condition (Hingorani et al.,
2003, 2005; Hruban et al., 2006). Of parti-
cular interest is that KPC mice, which con-
ditionally express endogenous mutant
Kras and p53 alleles in pancreatic cells,
have, as a very early histologic feature of
tumorigenesis, the appearance of a char-
acteristic stroma with infiltration of regula-
tory T cells, fibroblasts, and a fibroinflam-
matory component.
In an important follow-up study, Olive
and colleagues (2009) now demonstrate
that an Hh-signaling pathway antagonist
could be used to deplete tumor-associ-
ated stromal tissues and improve the
delivery of one of the few modestly active
anti-pancreatic-cancer agents, gemcita-
bine, into the pancreatic cancer. They
first show that tumors in KPC mice hadr Cell 16, July 7, 2009 ª2009 Elsevier Inc. 7
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Previewsdysfunctional vasculatures compared with
transplanted tumors. They also demon-
strate that blood vessel density was mark-
edly decreased and that only a few vessels
were embedded in a prominent stromal
matrix in the pancreatic cancers in the
KPC mice. Finally, they note, using an au-
tofluorescent chemotherapeutic agent
doxorubicin, that there was a ‘‘marked’’
decrease in drug delivery to pancreatic
tumors in KPC mice. The agent that they
selected to attempt to modify the stroma
was an inspired choice, given the fact
that paracrine Hh signaling for tumor cells
to normal cells has been documented to
‘‘promote stromal desmoplasia’’ (Yauch
et al., 2008; Bailey et al., 2008).
The Hh-signaling pathway has gener-
ated a tremendous amount of interest in
the cancer research community, with the
very substantial clinical activity of some
inhibitors of the pathway (smoothened
antagonists), such as GDC0449. This
substantial clinical activity has so far
been limited to tumor types that have
intrinsic activated Hh pathway due to
mutations in the patched 1 or smooth-
ened genes, such as advanced basal
cell carcinoma.
Olive and team demonstrate convinc-
ingly that, by treating mice with the Hh-
signaling inhibitor IPI-926 (also a smooth-
ened antagonist), there is improved
anticancer drug delivery to pancreatic
cancer in KPC mice. They also show
that the Hh-signaling pathway antagonist
can intercept the activation of Gli family
transcription factors and thus inhibit the
generation of the stromal desmoplasia.
Importantly, they demonstrate that oral
IPI-926 resulted in accumulation of anti-
cancer agents in the tumor tissue along
with a decrease in expression of Gli1,
a depletion in the desmoplastic stroma, a
decrease in a-smooth muscle actin-posi-
tive stromal fibroblasts, and a decrease
in collagen I content after 8–12 days of
treatment. The depletion of desmoplastic
stroma was accompanied by an increase
in mean vessel density and improved
delivery of both doxorubicin and gemcita-
bine (60% increase) to the pancreatic
cancer cells.
The use ofan inhibitor of the Hh-signaling
pathway to alter the stroma, increase intra-
tumoral vascular density, and improve the
delivery of a therapeutic agent certainly
gives clinicians, currently somewhat bereft
of ideas, a different way to tackle this
incredibly difficult disease. This work is
promptly being followed up with a clinical
trial. The clinical availability of Hh-signaling
pathway antagonists enables us to try.
Some investigators might feel that the
increased drug transport by IPI-926 treat-
ment is modest at best with only a modest
Figure 1. CT and MRI Demonstrate Hypoperfusion of Pancreatic Cancer
Hypoperfusion of pancreatic cancer on computer tomography (left) and on magnetic resonance image
(right) as evidenced by less contrast material in the tumor (note circled areas).8 Cancer Cell 16, July 7, 2009 ª2009 Elsevier Inc.increase inantitumor activity, and the effect
unfortunately is short lived. However, at the
very least, this study has once again awak-
enedus to the importanceof the vascularity
and stromal issues of adenocarcinoma of
the pancreas.
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